Recursion Pharmaceuticals
A deep look at Recursion Pharmaceuticals's finances, team, and market position in the AI Healthcare space.
Awaira Score
Out of 100
HQ
United States
Founded
2013
Stage
Public
Team
800
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a computational biology company founded in 2013 that uses artificial intelligence and high-throughput screening to accelerate drug discovery and development. The company's platform combines automated microscopy, machine learning, and large-scale biological data analysis to identify novel drug candidates and therapeutic targets across multiple disease areas. Recursion…
Key Facts
- Recursion Pharmaceuticals is valued at $1.79B as of March 2026.
- Recursion Pharmaceuticals was founded in 2013 by Chris Gibson and is headquartered in United States.
- Recursion Pharmaceuticals employs approximately 800 people.
- Recursion Pharmaceuticals operates in the AI Healthcare category and is currently at the Public stage.
- Recursion Pharmaceuticals has an Awaira Score of 65/100, ranking it among the tracked AI companies on Awaira.
- Recursion Pharmaceuticals's most recent funding round was a IPO closed in April 2021.
Source: Awaira · Updated Mar 24, 2026
Valuation
$1.79B
Post-money
Total Raised
N/A
All rounds
Awaira Score
65/100
Founded
2013
800 employees
Strengths & Risks
Strengths
Unicorn status with $1.79B valuation
Strong Awaira Score of 65/100
Growing team of 800 employees
Considerations
Limited disclosed funding
Analysis based on publicly available data. Not investment advice.
Funding Velocity
5
Total Rounds
$60.93M
Avg Round Size
7.3yr
Funding Span
Recursion Pharmaceuticals raised 5 rounds over 7.3 years, averaging $60.93M per round — a pace of roughly one round every 18 months.
Awaira estimate based on public data. Not financial advice.
How does Recursion Pharmaceuticals stack up against competitors?
Competitor Comparison
| Metric | ★Recursion Pharmaceuticals | Butterfly Network | Tempus | Alan |
|---|---|---|---|---|
| Awaira Score | 65/100 | 85/100 | 84/100 | 83/100 |
| Total Raised | N/A | $370M | $1.05B | $750M |
| Valuation | $1.79B | $957M | $8.1B | $5.83B |
| Stage | Public | Public | Public | Series D |
| Founded | 2013 | 2011 | 2015 | 2016 |
| Employees | 800 | 500-1000 | 2500 | 500-1000 |
| Country | 🇺🇸 | 🇺🇸 | 🇺🇸 | 🇫🇷 |
Funding Rounds
InactiveUndisclosed
Apr 2021
$121M
Jan 2021
$50M
Jan 2018
$60M
Jan 2017
$12.7M
Jan 2014
Recursion Pharmaceuticals Latest News
Casdin Partners Increases Position in Recursion Pharmaceuticals' AI Drug Discovery
Flagship Pioneering Invests in Recursion's AI Drug Discovery Platform
Recursion Pharmaceuticals Raises $300 Million for AI Drug Discovery
Recursion Pharmaceuticals Launches Next-Generation AI Capabilities for Enterprise Customers
Recursion Pharmaceuticals Reports Strong Growth as AI Industry Accelerates
Open Positions at Recursion Pharmaceuticals
View all jobs →Founded Same Year (2013)
Similar by Funding Stage (Public)
More from United States
🇺🇸 View all AI companies in United States →If you're looking at Recursion Pharmaceuticals, also check out
View all AI Healthcare →People Also Viewed
Frequently Asked Questions
What is Recursion Pharmaceuticals's valuation?▾
Who invested in Recursion Pharmaceuticals?▾
When did Recursion Pharmaceuticals last raise funding?▾
How many employees does Recursion Pharmaceuticals have?▾
What does Recursion Pharmaceuticals do?▾
Who founded Recursion Pharmaceuticals?▾
Is Recursion Pharmaceuticals profitable?▾
Where is Recursion Pharmaceuticals headquartered?▾
Compare Recursion Pharmaceuticals
See how Recursion Pharmaceuticals stacks up against competitors in valuation, funding, team size, and Awaira Score.